Your browser doesn't support javascript.
loading
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Harter, Philipp; Johnson, Toby; Berton-Rigaud, Dominique; Park, Sang-Yoon; Friedlander, Michael; Del Campo, Josep M; Shimada, Muneaki; Forget, Frédéric; Mirza, Mansoor R; Colombo, Nicoletta; Zamagni, Claudio; Chan, John K; Imhof, Martin; Herzog, Thomas J; O'Donnell, Dearbhaile; Heitz, Florian; King, Karen; Stinnett, Sandy; Barrett, Catherine; Jobanputra, Minesh; Xu, Chun-Fang; du Bois, Andreas.
Afiliação
  • Harter P; Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany. Electronic address: p.harter@gmx.de.
  • Johnson T; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.
  • Berton-Rigaud D; Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Saint-Herblain, France.
  • Park SY; National Cancer Center, Goyang, Republic of Korea.
  • Friedlander M; The Prince of Wales Clinical School University of New South Wales, Randwick, NSW, Australia.
  • Del Campo JM; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
  • Shimada M; Department of Obstetrics and Gynecology, Tottori University School of Medicine, Nishimachi, Yonago, Japan.
  • Forget F; Centre Hospitalier de l'Ardenne, Libramont, Belgium.
  • Mirza MR; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
  • Colombo N; Gynecologic Oncology, University of Milan-Bicocca and European Institute of Oncology, Milan, Italy.
  • Zamagni C; S. Orsola-Malpighi University Hospital, Bologna, Italy.
  • Chan JK; California Pacific and Palo Alto Sutter Cancer Research Institute, San Francisco, CA, USA.
  • Imhof M; Regional Hospital Korneuburg, Medical University of Vienna, Austria.
  • Herzog TJ; University of Cincinnati Cancer Institute, Cincinnati, OH, USA.
  • O'Donnell D; All Ireland Cooperative Oncology Research Group, Dublin, Ireland.
  • Heitz F; Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
  • King K; Parexel International, Durham, NC, USA.
  • Stinnett S; Parexel International, Durham, NC, USA.
  • Barrett C; Novartis Pharma AG, Basel, Switzerland.
  • Jobanputra M; Biogen Idec, Berkshire, UK.
  • Xu CF; GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.
  • du Bois A; Department of Gynecology & Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
Gynecol Oncol ; 140(3): 443-9, 2016 Mar.
Article em En | MEDLINE | ID: mdl-26740259
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Peritoneais / Pirimidinas / Sulfonamidas / Mutação em Linhagem Germinativa / Neoplasias Epiteliais e Glandulares / Genes BRCA1 / Genes BRCA2 / Neoplasias das Tubas Uterinas / Antineoplásicos Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Peritoneais / Pirimidinas / Sulfonamidas / Mutação em Linhagem Germinativa / Neoplasias Epiteliais e Glandulares / Genes BRCA1 / Genes BRCA2 / Neoplasias das Tubas Uterinas / Antineoplásicos Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article